Stakeholder Advice To Add-On Aspirants: Meet With CMS Prior To Approval
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking new-technology "add-on" payments under CMS' inpatient prospective payment system should meet with the agency well before a product gains premarket approval, according to Hospital & Ambulatory Group Director Liz Richter
You may also be interested in...
CMS New Tech Add-On Interpretation Contested By Industry Reps
Medtronic will attempt to persuade CMS that the firm's Kinetra deep-brain stimulation device marks a substantial clinical improvement over its predecessor - the dual-implant Soletra - and therefore qualifies for a new technology "add-on" payment
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.